KAPPA/LAMBDA FREE LIGHT CHAINS, QUANTITATIVE, WITH RATIO, SERUM
- KAPPA/LAMBDA FREE LIGHT CHAINS, QUANTITATIVE, WITH RATIO, SERUM
- Start Date
- Expiration Date
- Immunoglobulins, free light chain
- CPT Codes
- 83883 x 2
- Reference Test
- ATLAS Test Code
- Transport Info
Centrifuge and immediately transfer serum to separate plastic tube
- Fasting Required?
- Patient Instructions
- Reference Range
Free Kappa: Less than or equal to 22.2 mg/L
Free Lambda: Less than or equal to 34.4 mg/L
Ratio Kappa/Lambda: 0.410-1.430
Latex-Enhanced, Nephelometric Immunoassay
Measurements of free light chains in serum or urine aid in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloidosis, light chain deposition disease, and connective tissue diseases such as systemic lupus erythematosus.
Free light chains (FLC) is a more sensitive test than serum or urine immunofixation (IF) and it is a valuable tool for diagnosing and monitoring patients with secretory and nonsecretory multiple myeloma. Nearly all multiple myeloma patients have increased FLC. Monitoring of FLC provides a quicker indication of response to therapy than monoclonal or total immunoglobulins due to its shorter half-life and the larger clinical ranges of FLC concentrations. 100% of patients with light-chain multiple myeloma, 75% with nonsecretory myeloma, and more than 95% with primary amyloidosis could be diagnosed using FLC.